sDNA Test in Empfehlungen des ACS´s- Exact Science vor Wende? - 500 Beiträge pro Seite

[Schapekop]

Heute machen alle EXAS Aktionäre ein Freude-Tänzschen


Ich mache einfach mit.

Colorectal Cancer Screening Guidelines Released by the American Cancer Society Include EXACT Sciences' Stool DNA Technology
Thursday March 6, 7:30 am ET
Non-invasive Screening Option Has Potential to Save More Lives


MARLBOROUGH, Mass.--(BUSINESS WIRE)--EXACT Sciences Corporation (NASDAQ: EXAS - News) announced today that the Company’s non-invasive, stool-based DNA (sDNA) technology is included in the updated guidelines for colorectal cancer screening released by the American Cancer Society’s (ACS). The guidelines were developed by the ACS in collaboration with the U.S. Multi-Society Task Force on Colorectal Cancer (a group comprised of representatives from the American College of Gastroenterology, American Gastroenterological Association, and American Society for Gastrointestinal Endoscopy), and the American College of Radiology.
ADVERTISEMENT


“In addition to colonoscopy and other previously recommended tests, two new options have been included in the guidelines for colorectal cancer screening; stool DNA testing and CT colonography,” said Dr. Sidney Winawer, Attending Gastroenterologist and Paul Sherlock Chair in Medicine at Memorial Sloan-Kettering Cancer Center. “We hope that these two new options will encourage more people to come in to be screened so that the death rates of this cancer can be further reduced.”

EXACT Sciences developed its sDNA technology based on the groundbreaking work of Drs. Bert Vogelstein, Kenneth Kinzler and colleagues at Johns Hopkins University, who discovered how colorectal cancer develops at the molecular level. Over time, cells lining the colon accumulate alterations and mutations in their DNA. Pre-cancerous lesions, such as adenomas, and colorectal cancers continuously shed cells into the stool. The altered DNA from these cells is released as the cells breakdown in the stool. EXACT’s stool-based DNA technology was designed so that a stool sample could be collected in the privacy of one’s home and shipped to a laboratory for testing. The laboratory isolates and amplifies the DNA from the sample, and analyzes it for DNA mutations and alterations that are known to be associated with colorectal cancer.

“These updated guidelines are a strong endorsement of sDNA technology for detecting colorectal cancer, and a major step forward for the millions of Americans over the age of 50 who have been unwilling or unable to use existing screening methods for detecting colorectal cancer,” said Jeffrey Luber, President of EXACT Sciences Corporation. “Because sDNA technology is a completely non-invasive approach that does not require bowel preparation, published studies demonstrate strong patient preference and compliance with sDNA screening relative to other methods. We believe that these benefits will facilitate more screening and lead to more lives saved over time.”

"The colorectal cancer screening guidelines released by the American Cancer Society are an important event in the battle against colon cancer," said David King, President and CEO of Laboratory Corporation of America, licensee of EXACT's stool-based DNA screening technologies. "We applaud the committee's decision to include this important non-invasive technology in the guidelines."

Colorectal cancer is the most deadly cancer among non-smoking men and women in the United States, and the second most deadly cancer overall. It is estimated that nearly 150,000 cases will be diagnosed and 50,000 deaths are anticipated in 2008 due to this disease.1 Despite the availability of colorectal cancer screening and diagnostic tests for more than 20 years, the rate of early detection of colorectal cancer remains low, and deaths remain high. It is estimated that roughly one-third of colorectal cancer-related deaths could be saved if more people underwent regular screening. Early diagnosis results in a greater than 90 percent, five-year survival rate.

The new colorectal cancer screening guidelines are expected to appear in the May/June issue of CA: A Cancer Journal for Clinicians and are published early online in CA First Look at http://caonline.amcancersoc.org/. They are also expected to be published in the upcoming issues of the journals Gastroenterology and Radiology.

EXACT Sciences will hold a conference call to discuss the updated national colorectal cancer screening guidelines, as well as other business activities, including the Company’s recent meeting with the U.S. Food and Drug Administration and current regulatory strategy at 4:30pm ET today, March 6, 2008.

[Schapekop]

Auf diesen Tag haben EXAS Aktionäre viele Jahre gewartet, die ACS Guidelines kommen immerhin nur jede 4-6 Jahre raus.

Bedeutet zugleich Vergütung durch Medicare in die nahe Zukunft- nur sind noch was Problemchens mit der FDA zu regeln. Aber ist alles halb so wild.